Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations
Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates
Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations
Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates
Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates
Strong Trial Results, Effective Distribution Could Put Regeneron's Praluent 'Back In The Competition'
Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates
Strong Trial Results, Effective Distribution Could Put Regeneron's Praluent 'Back In The Competition'
Amgen 'Disappointed' In Court Decision To Reverse Praluent Sales Ban
Sanofi May Now Have Moved Past Its Most Challenging Period, Analyst Initiates At Buy
Praluent Recent News
Stay Of Court Injunction A Mild Positive For Regeneron
Catalyst Alert: Amgen/Regeneron Patent Case Appeal Could Be Decided By April
Why The Amgen/Regeneron Patent Saga Is Far From Over
Low Odds Court Ruling Against Regeneron Get Reversed On Appeal
The Medicines Co. Is A Top Pick For 2017
Regeneron Eyes A Comeback In 2017
Regeneron Is 'One Of The Stronger Growers In Biotech'
Regeneron Pharmaceuticals Loses 7% Following Q4 Miss
Chardan Downgrades Regeneron Pharmaceuticals, Notes Valuation Concerns
FDA Panel Clears Product Path For Sanofi, Regeneron Pharmaceuticals
Regeneron Earnings: Small Growth Expected, Driven By Eylea
UPDATE: Barclays Initiates Coverage On Regeneron